AstraZeneca’s LogicBio Buyout Will Give Other Troubled Gene Therapy Companies Hope

Rock Bottom Prices May Tempt Big Pharma

 
• By Andrew McConaghie
  
Astrazeneca
AstraZeneca's Alexion division has picked up the company at a bargain price of $68m, even while paying six times its market value.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Gene Therapies

More from Advanced Therapies